MARKET

SLXN

SLXN

Silexion Therapeutics Corp
NASDAQ
1.890
-0.030
-1.57%
Opening 11:25 01/02 EST
OPEN
1.940
PREV CLOSE
1.920
HIGH
1.940
LOW
1.825
VOLUME
26.08K
TURNOVER
--
52 WEEK HIGH
51.75
52 WEEK LOW
1.650
MARKET CAP
5.91M
P/E (TTM)
-0.0750
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SLXN last week (1222-1226)?
Weekly Report · 12/29/2025 10:16
Weekly Report: what happened at SLXN last week (1215-1219)?
Weekly Report · 12/22/2025 10:16
Maxim Group Sticks to Its Buy Rating for Silexion Therapeutics (SLXN)
TipRanks · 12/17/2025 14:17
Silexion Therapeutics Submits Phase 2/3 Trial Application
TipRanks · 12/16/2025 14:18
Silexion submits Phase 2/3 trial application to Israel for SIL204
TipRanks · 12/16/2025 13:45
Silexion Therapeutics Submits Regulatory Application To Israel For Its Phase 2/3 Clinical Study Of SIL204 In Participants With Locally Advanced Pancreatic Cancer
Benzinga · 12/16/2025 13:41
Silexion Therapeutics Submits Phase 2/3 Clinical Trial Application for SIL204 in Israel
Reuters · 12/16/2025 13:40
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer
Barchart · 12/16/2025 07:40
More
About SLXN
Silexion Therapeutics Corp is an oncology-focused biotechnology company. The Company is engaged in the development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.

Webull offers Silexion Therapeutics Corp stock information, including NASDAQ: SLXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLXN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLXN stock methods without spending real money on the virtual paper trading platform.